Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.